Pharma BD Deal Intelligence

Genentech / Alector, Inc.

2026 · Licensing/Option · $1.3B · Complete

On 2026-10-05 Alector granted Genentech (Roche Group) a global license to AL050, a preclinical brain-penetrant glucocerebrosidase (GCase) enzyme replacement therapy enabled by Alector's Alector Brain Carrier blood-brain-barrier delivery platform, for Parkinson's disease and other neurodegenerative indications. Alector receives USD 100M upfront and is eligible for up to USD 1.17B in development, regulatory and commercial milestones plus tiered royalties on net sales. Genentech assumes responsibility for development, regulatory activities, manufacturing and commercialization across all indications. Alector retains ownership of the ABC platform and full rights to apply it across its wholly owned pipeline.

This deal is too recent to grade. Critic Score and Outcome Score are assigned after the announcement-week coverage settles and, for Outcome, after the 5-year post-close assessment window opens — expected 2031 at the earliest for this deal, once/if it closes.

Key facts

Related deals

See the full interactive analysis, sources & comparables →

← Browse all deals  ·  How we score deals

More: 2026 deals  ·  Genentech deals